SHTG Digest — Friday May 29, 2026

SHTG Digest — Tuesday June 16, 2026

A meta-analysis confirms olezarsen's strong efficacy across eight RCTs, a human kinetic study illuminates exactly how ANGPTL3 deficiency reshapes triglyceride-rich lipoprotein metabolism, and a JACC case report highlights the management challenges of severe HTG in pregnancy — while the industry stage is quiet mid-week but poised for major events: the FDA PDUFA date for Tryngolza in sHTG arrives June 30, and Arrowhead's SHASTA-3/4 phase 3 readout is expected this month.

SHTG Digest — Friday June 12, 2026

A quiet cycle on both fronts — no new top-tier lipid papers cleared the bar (the one journal hit, a Lancet D&E retrospective, was already covered Tuesday), and no fresh trade-press stories landed in the 5-day window, leaving the competitive backdrop dominated by the countdown to the FDA's June 30 decision on olezarsen in severe hypertriglyceridemia.

SHTG Digest — Tuesday June 9, 2026

A sweeping 25-year review of lipid medicine published today in *Lancet Diabetes & Endocrinology* maps the journey from statins to RNA/DNA-targeted therapies for APOC3 and ANGPTL3; on the industry side, it's a quiet news week, but the Ionis FDA clock for Tryngolza in severe hypertriglyceridemia is now ticking down to a June 30 decision.

SHTG Digest — Friday June 5, 2026

Circulation Research publishes a landmark trio of review articles on triglyceride-rich lipoprotein biology and RNA-targeted therapies today, while on the industry side it is a quiet week — but the Ionis Tryngolza FDA decision in sHTG is now just 25 days away and Arrowhead's SHASTA-3/4 phase 3 readouts are imminent.

SHTG Digest — Tuesday June 2, 2026

A PNAS study reveals GPIHBP1 on brain oligodendrocytes as a novel docking site for LPL in the CNS, while an updated meta-analysis consolidates olezarsen's case as a potent APOC3-targeting therapy; on the industry side, a quiet week ahead of Ionis' looming June 30 FDA decision for Tryngolza in sHTG.